Market Intelligence, Clinical Progress, and High-Purity Reagents for Muscle Wasting and Metabolic Disease Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for WFIKKN2 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | WFIKKN2 Recombinant Protein (HEK293 Expressed, Native Glycosylation) High purity (>95%), Endotoxin Controlled, Sequence Verified. Available with Fc or His tags. |
View WFIKKN2 Products |
| Gene Delivery | WFIKKN2 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation and expression validation. |
View WFIKKN2 Products |
| Benchmark Ab | Anti-WFIKKN2 Recombinant Antibody Recombinant positive control derived from benchmark research sequences. |
View WFIKKN2 Products |
| Validator | WFIKKN2 siRNA Set Target-specific knockdown verification in cell-based assays. |
View WFIKKN2 Products |
| Related Target A | MSTN (Myostatin / GDF8) Primary therapeutic target regulated by WFIKKN2; critical for muscle hypertrophy assays. |
View MSTN Products |
| Related Target B | GDF11 Homologous TGF-beta family member co-regulated by WFIKKN2; essential for selectivity profiling. |
View GDF11 Products |
| Related Target C | ACVR2B (Activin Receptor Type IIB) Downstream signaling receptor; key component in competitive binding assays. |
View ACVR2B Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Multidomain folding & complex disulfide bonds (WAP, Follistatin, Kazal, Ig, Kunitz, Netrin domains) | Exclusively HEK293 expressed to ensure native eukaryotic post-translational modifications and correct folding. |
| Distinguishing MSTN vs. GDF11 binding kinetics | High-purity, sequence-verified MSTN and GDF11 proteins available for comparative SPR/BLI kinetics. |
| Lack of standardized assay controls | Recombinant benchmark antibodies and validated siRNA sets included in the ecosystem. |
| Inconsistent assay readouts due to endotoxin interference | Strict endotoxin control (<1.0 EU/μg) across all recombinant antigen batches. |
Live WFIKKN2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for WFIKKN2 (also known as GASP-1) therapeutics is intensifying, with major players shifting focus from general TGF-beta inhibition to highly selective muscle-preservation pathways. As next-generation obesity therapies (such as GLP-1 receptor agonists) face the challenge of lean mass loss, WFIKKN2 and its downstream targets (MSTN/GDF11) have emerged as premier targets for preserving muscle quality. The next wave of R&D is targeting highly specific antibody-mediated modulation of WFIKKN2 interactions to avoid systemic off-target toxicities associated with broad activin receptor blockade.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibodies (mAbs) | Regeneron, Scholar Rock, Eli Lilly | Sarcopenia, Duchenne Muscular Dystrophy (DMD), Muscle Wasting in GLP-1 therapies | High-affinity binding assays (Requires native HEK293-expressed WFIKKN2) |
| Recombinant Proteins / Decoys | Academic Institutions, Biotech Startups | Muscle Atrophy, Cachexia, Fibrosis | Ligand-receptor competition assays (Requires high-purity MSTN/GDF11 and ACVR2B) |
| Gene Therapy (AAV/Lentivirus) | Solid Biosciences, Specialized Gene Therapy Biotechs | Genetic Muscular Dystrophies | Overexpression validation (Requires sequence-verified Lentivirus / Promise-ORF) |